Related Experiment Video
Updated: Jan 21, 2026

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors
Ronald M Sánchez-Ávila1, Álvaro Fernández-Vega González1, Álvaro Fernández-Vega Sanz1
1University Institute Fernández-Vega, Ophthalmological Research Foundation, Oviedo, Spain.
Purpose:
To describe the case of a patient with a recurrent large myopic macular hole (MH), who was successfully treated with a plasma rich in growth factors (PRGF) membrane.
Case Report:
A 71-year-old patient presented a myopic MH in his right eye. One month later, pars plana vitrectomy with internal limiting membrane (ILM) peeling was performed, achieving closure of the MH. Three months later a recurrence was observed (700 µm) without visual acuity (VA) improvement. A new surgery was carried out placing an autologous PRGF-membrane into the MH, and performing a fluid-gas exchange at the end of the surgery. After two months of follow-up, the MH was completely closed, obtaining the anatomic recovery of the foveal depression, and improving the VA to 0.1. No adverse reactions were associated with the use of PRGF and there were no new recurrences of the MH in a follow-up period of six months.
Conclusion:
The use of PRGF-membrane can be used as adjunctive therapy in the surgical repair of recurrent large myopic MHs, thus improving anatomic and visual outcomes.
Insights
This study shows that a plasma rich in growth factors (PRGF) membrane effectively treated a recurrent large myopic macular hole (MH). The PRGF membrane aided in the anatomic recovery and improved visual acuity in the patient.
Area of Science:
- Ophthalmology
- Regenerative Medicine
Background:
- Recurrent large myopic macular holes (MH) pose a significant challenge in retinal surgery.
- Standard surgical interventions may not always achieve complete closure or long-term success.
Purpose of the Study:
- To report a case of successful treatment for a recurrent large myopic macular hole (MH).
- To evaluate the efficacy of a plasma rich in growth factors (PRGF) membrane as an adjunctive therapy.
Main Methods:
- A 71-year-old patient with a recurrent large myopic MH underwent pars plana vitrectomy with internal limiting membrane peeling.
- An autologous PRGF-membrane was applied to the macular hole, followed by a fluid-gas exchange.
- The patient was monitored for anatomical and visual outcomes.
Main Results:
- The PRGF-membrane facilitated complete closure of the recurrent macular hole.
- Anatomical recovery of the foveal depression was achieved.
- Visual acuity improved to 0.1, with no adverse reactions or recurrences observed during six months of follow-up.
Conclusions:
- Autologous PRGF-membrane serves as a viable adjunctive therapy for recurrent large myopic macular holes.
- This approach can significantly improve both anatomical and visual outcomes in challenging MH cases.
Related Concept Videos
Enlargement of the Plasma Membrane
Plasma Membrane in Bacteria and Archaea
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Fusion of Secretory Vesicles with the Plasma Membrane
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
Factors Influencing Microbial Growth: Temperature

